Neuropsychiatric Continuing Education

Stay informed while earning CME/CE credit

Neuropsychiatric disorders such as schizophrenia, bipolar disorder, and major depressive disorder are serious, debilitating, and clinically complex disorders that often pose a considerable challenge to clinicians. While practice guidelines may assist clinicians in management, clinical trial data is often rapidly emerging to identify evidence-based strategies to optimize clinical management.

Given the significant clinical and quality of life impact of neuropsychiatric disorders, the identification and implementation of safe, effective management strategies is paramount. The CME Outfitters Neuropsychiatric Hub is designed to provide clinicians with the latest clinical practice guidelines, diagnostic strategies and tools, and scientific updates on current and emerging therapies to optimize management of neuropsychiatric disorders.

Jump to:

 

Live & On-Demand Webcasts CMEOCast BriefCase Snack Animations

Clinical Resources Telehealth

Achieving Optimal Outcomes in Patients with Narcolepsy: Aligning Treatment Goals with Patients

 

Participate Now  

Join Drs. Bogan, Thorpy, and Weaver for an OnDemand symposium as they discuss evidence-based strategies to reduce EDS and cataplexy, among other symptoms, and restore quality of life and functioning in patients with narcolepsy.

Detect and Defeat: Improving Awareness of the Differences in Narcolepsy and Novel Strategies for Treatment

 

Participate Now  

Join expert faculty in this live and OnDemand initiative as they discuss effective tools and strategies to improve the accurate and early detection of narcolepsy, as well as the latest evidence on optimal treatment strategies to achieve sustained benefits by improving clinical outcomes and facilitating adherence.

A Clinical Wake Up Call: Diagnostic Strategies and Novel Therapies in Idiopathic Hypersomnia

 

Participate Now  

This CME Outfitters’ Live and OnDemand activity will feature expert faculty detailing the functional and clinical impact of IH, best practices and the latest tools for an accurate diagnosis, and the efficacy and safety of novel therapies and how they address the unmet needs of people with IH.

Turning the Tide on Patient Engagement, Treatment Adherence, and Continuity of Care in Schizophrenia: The Role of Long-Acting Injectables in Optimizing Outcomes

 

Participate Now  

This CME Outfitters webcast features a collaboration with the American Telemedicine Association (ATA) regarding best practices for incorporating telemedicine in psychiatric management, and will focus on shared decision-making, patient education, and utilizing telemedicine to assist in treatment adherence and supporting patients with schizophrenia.

The Complete Response: Addressing Antidepressant Failure in Patients with Major Depressive Disorder

 

Participate Now  

This CME Outfitters On-Demand virtual symposium will provide family medicine clinicians with real-world strategies to incorporate measurement-based care into routine practice to rapidly detect suboptimal treatment outcomes. In addition, faculty experts will guide family medicine clinicians through developing safe and effective alternate antidepressant therapy with unique MOAs when patients experience treatment failures with initial SSRIs/SNRIs.

Navigating the Neurophysiology of Sleep and Cataplexy: The Significance of Select Neurotransmitters

 

Participate Now  

Join Drs. Thorpy and Zee in part two of a CMEOCast series on excessive daytime sleepiness (EDS) in narcolepsy as they walk clinicians through identifying the mechanisms of action (MOAs) of novel therapies and differentiating the neurotransmitters involved when individualizing therapy selection for optimal outcomes.

Using Measurement-Based Care to Improve the Accurate, Early Detection of TD

 

Participate Now  

Join Drs. Correll and Jimenez-Shahed in this first installment of a CMEOCast series as they guide clinicians through the use of MBC to facilitate the early detection of TD and its routine monitoring. In addition, faculty will discuss the pathogenesis of TD, particularly within the context of antipsychotic use, and offer clinical pearls for personalizing treatment selection.

Making the Right Moves for the Long-Term Management of Antipsychotic-Induced TD: Evidence-Based Strategies to Improve Quality of Life and Patient-Centered Outcomes

 

Participate Now  

Join Drs. Correll and Jimenez-Shahed as they discuss the pathogenesis of TD and analyze the latest clinical evidence on the role of VMAT2 inhibitors in reducing the burden of TD and improving QoL and restoration of function in patients with TD.

The Impact of OSA-Related EDS on HRQoL: Time for a Wake-up Call

 

Participate Now  

Join Drs. Richard Bogan and Terri Weaver as they discuss case 1 of this 3-part CMEO BriefCase series and provide insight into the extensive impact of OSA-related EDS on psychosocial functioning and HRQoL to promote the need for early intervention.

Can We Talk: Strategies to Communicate Long-Acting Injectables (LAIs) as an Effective Treatment Option for Bipolar I Disorder

 

Participate Now  

This CMEO BriefCase utilizes a patient case to guide clinicians on best practices to engage patients in treatment planning for bipolar disorder-1, including the feasibility of LAIs as an effective treatment option.

Meeting the Challenge: Improving Diagnosis of ALS

 

Participate Now  

This is the first installment in a CMEOutfitters series on the role of genetic testing and emerging therapies in ALS and focuses on recognizing the challenges in diagnosing ALS.

Role of Genetics in ALS: Who Should Be Tested

 

Participate Now  

Given that the genetic landscape of ALS is rapidly changing, clinicians must be acquainted with recent advances and best practices. Join Dr. Andrews and Dr. Al-Chalabi in part 2 of this CMEOutfitter’s snack series as they discuss the utility of genetic testing in ALS.

Emerging Gene Therapies in the Fight Against ALS

 

Participate Now  

Given the modest efficacy of current ALS treatments, access to emerging therapies is critical. Clinicians must be up-to-date on efficacy, safety, clinical trial results, and access pathways for their patients. Join Dr. Andrews and Dr. Shefner in part 3 of this CMEOutfitter’s snack series as they discuss best practices for navigating the clinical trial landscape of ALS gene therapies.

Understanding the True Costs of ADHD: An Examination of the Whole-Life Impact

 

Participate Now  

The first installment of this 4-part CME Outfitters series on ADHD will feature a discussion by Drs. Ann Childress and Thomas E. Brown on the extensive burden and impact of ADHD in children and adults. Additionally, the activity will include the use of a 3-D model highlighting the various systems and domains impacted.

Can You ID ADHD? Tips and Tools to Improve Your Rate of Detection in Adults

 

Participate Now  

This CME Outfitters activity will provide clinicians with the appropriate tools to facilitate the early detection of ADHD in adults, particularly within the context of comorbidities.

Moving Beyond Limitations in ADHD Management: Best Practices for Personalized Therapy for Children and Adults

 

Participate Now  

For clinical pearls on optimal strategies to personalize care for children and adults with ADHD, join our faculty experts for this third installment in the CME Outfitters series “ADHD Can Be a Moving Target: Equip Yourself with the Tools to Detect and Manage ADHD to Reduce Its Burden.”

Empowering Patients to Make Informed Treatment Decisions in ADHD: What They Need to Know

 

Participate Now  

For insight on ADHD medication profiles, behavioral therapies, and supportive strategies to enhance treatment adherence, join our faculty experts for this fourth installment in the CME Outfitters series “ADHD Can Be a Moving Target: Equip Yourself with the Tools to Detect and Manage ADHD to Reduce Its Burden.”

Schizophrenia is a Whole-Body Disease: Examining the Impact of Comorbidities on Morbidity and Mortality

 

Participate Now  

In the first installment of this CME Outfitters Snack series on schizophrenia, faculty experts will provide clinicians with tools to identify and mitigate the impact of medical comorbidities on morbidity and mortality risks.

Long-acting Injectables in Schizophrenia: An Evidence-Based Strategy to Get Your Patients to Remission and Recovery

 

Participate Now  

In this 2nd episode of a three-part CME Outfitters Snack series on schizophrenia, faculty will review the latest clinical evidence on LAIs and provide clinicians with tips for personalizing treatment selection and initiation, considering dose and dosing schedules.

Animations

ADHD: Comorbidities and Risks

In this video, Dr. Ann Childress addresses stigmas associated with ADHD and reviews the wide array of comorbid conditions that can be present in individuals with ADHD.

ADHD: Brain Mechanisms Involved

In this video, Dr. Ann Childress discusses morphology of the ADHD brain. 

Clinical Resources

Inventories

  • Mood Disorder Questionnaire (MDQ) The Mood Disorder Questionnaire (MDQ) can be administered either by the clinician or self-administered by the patient. The MDQ consists of 15 questions and takes about 5 minutes to complete.
  • Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16) Quick Inventory of Depressive Symptomatology (Self-Report) (QIDS-SR-16) has proven useful for many years as a way of determining a patient’s level of depression before, during, and after treatment.
  • Bipolar Spectrum Diagnostic Scale (BSDS) The Bipolar Spectrum Diagnostic Scale (BSDS) is a descriptive story that captures subtle features of bipolar illness.
  • Beck Depression Inventory-II (BDI-II) The Beck Depression Inventory-II (BDI-II): 1996 revision of the BDI 21-item self-report multiple-choice inventory ~ 10 minutes to complete. Widely used indicator of the severity of depression.
  • Patient Health Questionnaire (PHQ-2) Use the Patient Health Questionnaire (PHQ-2) to screen for depression.
  • Edinburgh Postnatal Depression Scale (EPDS) Proven to be an effective screening tool to identify patients at risk for “perinatal” depression. Mother asked to check the response that comes closest to how she has been feeling in the previous 7 days.
  • Geriatric Depression Scale Short Form (GDS-SF) 15-item screening tool used to identify depression in older adults
  • Hamilton Depression Rating Scale (HAM-D) The Hamilton Depression Rating Scale (HAM-D) has proven useful for many years as a way of determining a patient’s level of depression before, during, and after treatment.
  • Brief Psychiatric Rating Scale (BPRS) Comprehensive 24-item symptom scale
  • Medication Adherence Rating Scale (MARS) The total score ranges from 0-10 with a higher score indicating better adherence
  • Brief Adherence Rating Scale (BARS)

Telehealth

What is telehealth and how can I use it?

Download Whiteboard Video  

Discover additional accredited CME/CE activities and patient resources on the Virtual Education Hub.

Visit the Hub